10.1002/adsc.201701046
Advanced Synthesis & Catalysis
[3] J. H. Teles, G. Maier, Chem. Ber. 1989, 122, 745.
a review on nitrogen-substituted isocyanates allowing a
comparison with other methods to form N-isocyanates,
see: f) J.-F. Vincent-Rocan, A. M. Beauchemin, Synthesis
2016, 48, 3625.
[4] Wentrup has also performed computational experiments
on O-isothiocyanates: C. Wentrup, J. J. Finnerty, R. Koch,
Curr. Org. Chem. 2011, 15, 1745.
[13] In order of compounds in Figure 1B (left to right): a) H.
Gmunder, K. Kuratli, W. Keck, Antimicrob. Agents
Chemother. 1995, 39, 163; b) G. Bridger, E. J.
McEachern, R. Skerlj, D. Schols (Genzyme Corp),
US2004/209921 A1, 2004; Location in patent: Page 72;
c) A. B. Cognetta III, M. J. Niphakid, H.-C. Lee, M. L.
Martini, J. J. Hulce, B. F. Cravatt, Chem. Biol. 2015, 22,
928; d) D. Catarzi, V. Colotta, F. Varano, Med. Res. Rev.
2007, 27, 239; e) G. P. Jadhav, I. Kaur, M. Maryati, B.
Airhihen, P. M. Fischer, G. S. Winkler, Bioorg. Med.
Chem. Lett. 2015, 25, 4219; f) D. Y. Wang, M. I. Abboud,
M. S. Markoulides, J. Brem, C. J. Schofield, Future Med.
Chem. 2016, 8, 1063.
[5] C. S. Jamieson, A. M. Mebel, R. I. Kaiser, Phys. Chem.
Chem. Phys. 2005, 7, 4089.
[6] For a single example of O-isocyanates in synthesis see: J.
L. Romine, S. W. Martin, N. A. Meanwell, J. R. Epperson,
Synthesis 1994, 846. For examples that likely go through
O-isocyanates see: R. E. Beevers, G. M. Buckley, N.
Davies, J. L. Fraser, F. C. Galvin, D. R. Hannah, A. F.
Haughan, K. Jenkins, S. R. Mack, W. R. Pitt, A. J.
Ratcliffe, M. D. Richard, V. Sabin, A. Sharpe, S. C.
Williams, Bioorg. Med. Chem. Lett. 2006, 16, 2539; b) J.
F. Berry, D. V. Ferraris, B. Duvall, N. Hin, R. Rais, J. Alt,
A. G. Thomas, C. Rojas, K. Hashimoto, B. S. Slusher, T.
Tsukamoto, ACS Med. Chem. Lett. 2012, 3, 839.
[14] D. Leung, G. Abbenante, D. P. Fairlie, J. Med. Chem.
2000, 43, 305.
[7] For examples of unexpected Lossen rearrangements
forming O-isocyanates see: a) S. Hanessian, S. Johnstone,
J. Org. Chem. 1999, 64, 5896; b) S. Fioravanti, F.
Marchetti, A. Morreale, L. Pellacani, P. A. Tardella, Org.
Lett. 2003, 5, 119; c) J. G. Krause, B. D. Leskiw, M. L.
Emery, M. E. McGahan, M. P. McCourt, R. Priefer,
Tetrahedron Lett. 2010, 51, 3568; d) T. Baburaj, S.
Thambidurai, Synlett 2011, 1993; e) T. Baburaj, S.
Thambidurai, Tetrahedron Lett. 2012, 53, 2294.
[15] For
reviews
on
hydroxamates
as
matrix
metalloproteinase inhibitors see: a) M. Whittaker, C. D.
Floyd, P. Brown, A. J. H. Gearing, Chem. Rev. 1999, 99,
2735; b) M. Hidalgo, S. G. Eckhardt, J. Natl. Cancer Inst.
2001, 93, 178; c) J. W. Skiles, N. C. Gonnella, A. Y. Jeng,
Curr. Med. Chem. 2004, 11, 2911; d) B. Govinda Rao,
Curr. Pharm. Design, 2005, 11, 295; e) G. G. Tu, W. F.
Xu, H. M. Huang, S. H. Li, Curr. Med. Chem. 2008, 15,
1388.
[8] For examples of trimerization of O-isocyanate
intermediates see: a) A. F. McKay, D. L. Garmaise, G. Y.
Paris, S. Gelblum, Can. J. Chem. 1960, 38, 343; b) H. A.
Staab, Angew. Chem. Int. Ed. 1962, 1, 351; c) M. T.
[16] L. Konnert, E. Colacino, Chem. Rev. 2017, ASAP (DOI:
10.1021/acs.chemrev.7b00067).
Randolph, T. J. Hendrick, J. Org. Chem, 1965, 30, 1268; [17] J.-F. Vincent-Rocan, C. Clavette, K. Leckett, A. M.
d) U, Heep, Tetrahedron, 1975, 31, 77. Beauchemin, Chem. Eur. J. 2015, 21, 10.
[9] a) Z. Li, H. Yamamto, Acc. Chem. Res. 2013, 46, 506; b) [18] For recent examples demonstrating the propensity of O-
K.-J. Xioa, D. W. Lin, M. Miura, R.-Y. Zhu, W. Gong, M.
Wasa, J.-Q. Yu, J. Am. Chem. Soc. 2014, 136, 8138.
acyl hydroxylamines to undergo Lossen rearrangements
under basic conditions see: a) Y. Hoshino, M. Okuno, E.
Kawamura, K. Honda, S. Inoue, Chem. Commun. 2009,
17, 2281; b) E-S. M. N. AbdelHafez, O. M. Aly, G. E-D
A. A. Abuo-Rahma, S. B. King, Adv. Synth. Catal. 2014,
356, 3456; c) N. Ohtsuka, M. Okuno, Y. Hoshino, K.
Honda, Org. Biomol. Chem. 2016, 14, 9046.
[10] For a recent review on hydroxamate directing groups
see: R.-Y. Zhu, M. E. Farmer, Y.-Q. Chen, J.-Q. Yu,
Angew. Chem. Int. Ed. 2016, 55, 10578.
[11] For reviews on the interesting biological properties of
hydroxamic acids see: a) P. A. Marks, R. A. Rifkind, V.
M. Richon, R. Breslow, T. Miller, W. K. Kelly, Nat. Rev.
Cancer, 2001, 1, 194; b) R. W. Johnstone, Nat. Rev. Drug.
[19] Upon prolonged heating at 175 ºC, sarcosine ethyl ester
hydrochloride began to decompose.
Discov. 2002, 1, 287; c) W. K. Kelly, P. A. Marks, Nat. [20] See reference 13c and citations therein.
Rev. Clin. Oncol. 2005, 2, 150; d) P. A. Marks, R. Breslow,
[21] P. Wu, T. E. Nielsen, Chem. Rev. 2017, 117, 7811.
Nature Biotechnol. 2007, 25, 84; e) C. Harrison, Nat. Rev.
Drug Discov. 2009, 8, 924; f) S. P. Gupta, Chem. Rev.
2015, 115, 6427.
[12] a) C. Clavette, J.-F. Vincent-Rocan, A. M. Beauchemin,
Angew. Chem. Int. Ed. 2013, 52, 12705; b) R. A.
Ivanovich, J.-F. Vincent-Rocan, E. B. Elkaeed, A. M.
Beauchemin, Org. Lett. 2015, 17, 4898; c) J.-F. Vincent-
Rocan, J. S. Derasp, A. M. Beauchemin, Chem. Commun.
2015, 51, 16405; d) J.-F. Vincent-Rocan, R. A. Ivanovich,
C. Clavette, K. Leckett, J. Bejjani, A. M. Beauchemin,
Chem. Sci. 2016, 7, 315; e) J. S. Derasp, J.-F. Vincent-
Rocan, A. M. Beauchemin, Org. Lett. 2016, 18, 658. For
5
This article is protected by copyright. All rights reserved.